🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

There’s still time to join us for the Edwards Lifesciences Sponsored Learning Studio at #AHA24. Reserve your spot now: bit.ly/3AdUq8t

Thanks for joining us at #AHA24 for our Learning Studio on challenges in symptomatic severe aortic stenosis treatment and contemporary outcomes with #TAVRbyEdwards. See the guidelines in practice with patient case reviews here: bit.ly/40G4TEy

Are we only halfway there getting patients to treatment? Data show over 50% of eligible patients don’t receive AVR. I’m highlighting how we can confront this critical health issue through multidisciplinary partnership with Edwards Lifesciences bit.ly/3Dtbdpl

Dear doctors—this #VALVEntinesDay, continue to protect your patients’ heart valve health by inviting them in for a routine screening. (Their hearts will thank you.) And be sure to share with them the Valventine’s Day promise at BeMyValventine.com.

Aortic stenosis threatens heart health, and increased severity means faster progression. I’m collaborating with Edwards Lifesciences to emphasize how referring severe patients early keeps sudden progression from going unchecked. Learn more: bit.ly/3VNTAqk

#ACC25 is just around the corner, and new trial outcomes have sparked a critical transformation in the management of severe Aortic Stenosis (AS). Come visit the Edwards booth to learn more about this groundbreaking trial. ow.ly/kJfE50VlF1l #TAVRbyEdwards

Did you know decision aids are tools that can improve efficiency during patient encounters? I'm collaborating with Edwards Lifesciences to share this evidence-based informed decision guide for severe aortic stenosis patients. Check it out: bit.ly/3DHHB8h #cardiosmart

STRIKE FAST at this year's #ACC25. Learn about how new trial outcomes have created a critical paradigm shift in the management of severe Aortic Stenosis (AS). ow.ly/sSbX50VlFw9 #TAVRbyEdwards

Looking for good conversation and hot coffee? Visit the Edwards booth at #ACC25 to catch up on the discussion! ow.ly/G8T250VlGl9 #TAVRbyEdwards

Try our lightning-fast quiz at the Edwards booth. Get your name on the leaderboard while learning about the latest in severe Aortic Stenosis management. ow.ly/jO9Z50VlGTJ #TAVRbyEdwards

Thanks to all who stopped by at #ACC25 to learn about recent trial outcomes and the importance of referral to a Heart Valve Team to strike severe Aortic Stenosis. We’ll see you soon. ow.ly/OM3050VlGYJ #TAVRbyEdwards

#ACC25 is over but the message is clear: Now is the time to strike against severe Aortic Stenosis (AS), because it can progress rapidly and unpredictably. Don’t wait to refer all appropriate severe AS patients to a Heart Valve Team. ow.ly/5lt450VlH1y #TAVRbyEdwards

Are we referring severe aortic stenosis patients at the right time? Data continue to suggest they can't afford to wait. I'm collaborating with Edwards Lifesciences on the benefit of a Heart Valve Team approach for managing these patients, regardless of symptoms. #hearthealth #cardioEd

The Early TAVR Trial: A Clinical Cardiologist’s Perspective dlvr.it/TKdtnc

The Heart Valve Matters' new series, "TAVR Now: How data-driven insights are transforming care," is here! In this episode, Bernard Prendergast and Philippe Genereux detail the EARLY TAVR trial design & outcomes from the interventionalist perspective. tctmd.com/audio/early-ta…

A paradigm shift in severe aortic stenosis (AS) care is now here. SAPIEN 3 TAVR is the first and only valve indicated for patients with asymptomatic severe AS. ⚠️ Important Safety Info: ow.ly/1yqJ50VQjOF

Edwards TAVR is now indicated to treat patients with asymptomatic severe aortic stenosis: bit.ly/3F6wsye ⚠️ Important Safety Info: bit.ly/4lF2uSz

The EARLY TAVR Trial: Best Practices for Referrer and Patient Engagement dlvr.it/TKnYz2

Actioning the Data: Earlier AS Referral in the Real World dlvr.it/TKnZ68

This summer, NY Valves returns. Join the excitement around the new Edwards Lifesciences TAVR indication at the Edwards symposium on Thursday 6/26. ow.ly/VGSi50WaW2n